Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Characterization of the common fragile site FRA9E and its potential role in ovarian cancer

Abstract

Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The major aim of this study was to locate a fragile region associated with ovarian cancer. Differential display (DD)-PCR analysis comparing normal ovarian epithelial cultures and ovarian cancer cell lines identified pregnancy-associated plasma protein-A (PAPPA) because of its frequent loss of expression (LOE) in ovarian cancer cell lines. PAPPA is localized to human chromosome 9q32–33.1, a region associated with significant loss of heterozygosity (LOH) in ovarian tumors (>50%) and in close proximity to the FRA9E CFS. FISH analysis determined that PAPPA was contained within the distal end of FRA9E. Characterization of FRA9E determined that aphidicolin-induced instability extended over 9 Mb, identifying FRA9E as the largest CFS characterized to date. Comprehensive LOH analysis revealed several distinct peaks of LOH within FRA9E. Semiquantitative RT–PCR analysis of 16 genes contained within FRA9E indicated that genes showing LOE in ovarian tumors coincided with regions of high LOH. PAPPA displayed the most significant loss (72%). This study provides evidence to suggest that instability within FRA9E may play an important role in the development of ovarian cancer and lends further support for the hypothesis that CFSs may be causally related to cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Arlt MF, Miller DE, Beer DG and Glover TW . (2002). Genes Chromosomes Cancer, 33, 82–92.

  • Becker NA, Thorland EC, Denison SR, Phillips LA and Smith DI . (2002). Oncogene (in Press).

  • Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA and Aldaz CM . (2000). Cancer Res., 60, 2140–2145.

  • Chen BK, Overgaard MT, Bale LK, Resch ZT, Christiansen M, Oxvig C and Conover CA . (2002). Endocrinology, 143, 1199–1205.

  • Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, Kalli KR and Jenkins RB . (1998). Exp. Cell Res., 238, 439–449.

  • Denison SR, Becker NA, Ferber MJ, Phillips LA, Kalli KR, Lee J, Lillie J, Smith DI and Shridhar V . (2002). Genes Chromosomes Cancer, 34, 406–415.

  • Durham SK, Riggs BL, Harris SA and Conover CA . (1995). Endocrinology, 136, 1374–1380.

  • Gabra H and Smyth JF . (1997). Biology of Female Cancers. Langdon SP, Miller WR, Berchuck A (eds). CRC Press: Boca Raton, FL, pp. 93–113.

    Google Scholar 

  • Glover TW, Berger C, Coyle J and Echo B . (1984). Hum. Genet., 67, 136–142.

  • Hamilton TC, Young RC and Ozols RF . (1984). Semin. Oncol., 11, 285–298.

  • Hewett DR, Handt O, Hobson L, Mangelsdorf M, Eyre HJ, Baker E, Sutherland GR, Schuffenhauer S, Mao JI and Richards RI . (1998). Mol. Cell, 1, 773–781.

  • Huang H, Qian C, Jenkins RB and Smith DI . (1998a). Genes Chromosomes Cancer, 21, 152–159.

  • Huang H, Qian J, Proffit J, Wilber K, Jenkins R and Smith DI . (1998b). Oncogene, 16, 2311–2319.

  • Jemal A, Thomas A, Murray T and Thun M . (2002). CA: Cancer J. Clin., 52, 23–47.

  • Jones C, Penny L, Mattina T, Yu S, Baker E, Voullaire L, Langdon WY, Sutherland GR, Richards RI and Tunnacliffe A . (1995). Nature, 376, 145–149.

  • Jones C, Slijepcevic P, Marsh S, Baker E, Langdon WY, Richards RI and Tunnacliffe A . (1994). Hum. Mol. Genet., 3, 2123–2130.

  • Kirschner LS and Stratakis CA . (1999). Biotechniques, 27, 72–74.

  • Knight SJL, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR, Pointon J, Middleton-Price HR, Barnicoat A, Pembrey ME . (1993). Cell, 74, 127–134.

  • Kruk PA, Maines-Bandiera SL and Auersperg N . (1990). Lab. Invest., 63, 132–136.

  • Krummel KA, Roberts LR, Kawakami M, Glover TW and Smith DI . (2000). Genomics, 69, 37–46.

  • Landis SH, Murray T, Bolden S and Wingo PA . (1998). CA: Cancer J. Clin., 48, 6–30.

  • Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates 3rd JR and Conover CA . (1999). Proc. Natl. Acad. Sci. USA, 96, 3149–3153.

  • Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE . (1998). Oncogene, 16, 1391–1397.

  • Lin TM, Galbert SP, Kiefer D, Spellacy WN and Gall S . (1974). Am. J. Obstet. Gynecol., 118, 223–236.

  • Mangelsdorf M, Ried K, Woollatt E, Dayan S, Eyre H, Finnis M, Hobson L, Nancarrow J, Venter D, Baker E and Richards RI . (2000). Cancer Res., 60, 1683–1689.

  • Mishmar D, Rahat A, Scherer SW, Nyakatura G, Hinzmann B, Kohwi Y, Mandel-Gutfroind Y, Lee JR, Drescher B, Sas DE, Margalit H, Platzer M, Weiss A, Tsui LC, Rosenthal A and Kerem B . (1998). Proc. Natl. Acad. Sci. USA, 95, 8141–8146.

  • Nancarrow JK, Kremer E, Holman K, Eyre H, Doggett NA, Le Paslier D, Callen DF, Sutherland GR and Richards RI . (1994). Science, 264, 1938–1941.

  • Oberle I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF and Mandel JL . (1991). Science, 252, 1097–1102.

  • Paige AJ, Taylor KJ, Stewart A, Sgouros JG, Gabra H, Sellar GC, Smyth JF, Porteous DJ and Watson JE . (2000). Cancer Res., 60, 1690–1697.

  • Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D, Porteous DJ, Smyth JF, Gabra H and Watson JE . (2001). Proc. Natl. Acad. Sci. USA, 98, 11417–11422.

  • Paradee W, Wilke CM, Wang L, Shridhar R, Mullins CM, Hoge A, Glover TW and Smith DI . (1996). Genomics, 35, 87–93.

  • Rassool FV, Le Beau MM, Shen ML, Neilly ME, Espinosa 3rd R, Ong ST, Boldog F, Drabkin H, McCarroll R and McKeithan TW . (1996). Genomics, 35, 109–117.

  • Ritchie RJ, Knight SJ, Hirst MC, Grewal PK, Bobrow M, Cross GS and Davies KE . (1994). Hum. Mol. Genet., 3, 2115–2121.

  • Schultz DC, Vanderveer L, Buetow KH, Boente MP, Ozols RF, Hamilton TC and Godwin AK . (1995). Cancer Res., 55, 2150–2157.

  • Silahtaroglu AN, Tumer Z, Kristensen T, Sottrup-Jensen L and Tommerup N . (1993). Cytogenet. Cell Genet., 62, 214–216.

  • Smith DI, Huang H and Wang L . (1998). Int. J. Oncol., 12, 187–196.

  • Sonoda G, Palazzo J, du Manoir S, Godwin AK, Feder M, Yakushiji M and Testa JR . (1997). Genes Chromosomes Cancer, 20, 320–328.

  • Stabile I, Grudzinskas JG and Chard T . (1988). Obstet. Gynecol. Surv., 43, 73–82.

  • Sutherland GR, Baker E and Richards RI . (1998). Trends. Genet., 14, 501–506.

  • Tatarelli C, Linnenbach A, Mimori K and Croce CM . (2000). Genomics, 68, 1–12.

  • Verkerk AJMH, Rieretti M, Sutcliffe JS, Fu Y, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van Ommen GB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra MA and Warren ST . (1991). Cell, 65, 905–914.

  • Verma RS and Babu A . (1989). Human Chromosomes: Manual of Basic Techniques. Verma RS, Babu A (eds). Pergamon Press Inc.: New York, p. 240.

    Google Scholar 

  • Wald NJ, George L, Smith D, Densem JW and Petterson K . (1996). Br. J. Obstet. Gynaecol., 103, 407–412.

  • Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI and Glover TW . (1996). Hum. Mol. Genet., 5, 187–195.

  • Yu S, Mangelsdorf M, Hewett D, Hobson L, Baker E, Eyre HJ, Lapsys N, Le Paslier D, Doggett NA, Sutherland GR and Richards RI . (1997). Cell, 88, 367–374.

  • Yunis JJ and Soreng AL . (1984). Science, 226, 1199–1204.

Download references

Acknowledgements

We thank Dr Kimberly Kalli and Kimberly Stephens for providing the short-term normal ovarian epithelial (OSE) cultures. This study was conducted as a component of GC's doctoral thesis requirements in the Mayo Graduate School. GC's training has been supported, in part, by an NIH training Grant (CA 75926) to the Tumor Biology Program of the Mayo Graduate School and by the Mayo Clinic Foundation. This work was supported by NCI Grant CA48031 and DOD Grant DAMD17-99-1-9504 (both to DIS).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David I Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Callahan, G., Denison, S., Phillips, L. et al. Characterization of the common fragile site FRA9E and its potential role in ovarian cancer. Oncogene 22, 590–601 (2003). https://doi.org/10.1038/sj.onc.1206171

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206171

Keywords

This article is cited by

Search

Quick links